Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis
Mostly, cardiovascular diseases are blamed for casualties in rheumatoid arthritis (RA) patients. Customarily, dyslipidemia is probably the most prevalent underlying cause of untimely demise in people suffering from RA as it hastens the expansion of atherosclerosis. The engagement of inflammatory cytokines like tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), etc., is crucial in the progression and proliferation of both RA and abnormal lipid parameters. Thus, lipid abnormalities should be monitored frequently in patients with both primary and advanced RA stages. An advanced lipid profile examination, i.e., direct role of apolipoproteins associated with various lipid molecules is a more dependable approach for better understanding of the disease and selecting suitable therapeutic targets. Therefore, studying their apolipoproteins is more relevant than assessing RA patients' altered lipid profile levels. Among the various apolipoprotein classes, Apo A1 and Apo B are primarily being focused. In addition, it also addresses how calculating Apo B:Apo A1 ratio can aid in analyzing the disease's risk. The marketed therapies available to control lipid abnormalities are associated with many other risk factors. Hence, directly targeting Apo A1 and Apo B would provide a better and safer option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Canadian journal of physiology and pharmacology - (2024) vom: 09. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Aditi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apolipoproteins |
|---|
| Anmerkungen: |
Date Revised 09.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1139/cjpp-2023-0259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368235742 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368235742 | ||
| 003 | DE-627 | ||
| 005 | 20240209232233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1139/cjpp-2023-0259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM368235742 | ||
| 035 | |a (NLM)38334084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Aditi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Mostly, cardiovascular diseases are blamed for casualties in rheumatoid arthritis (RA) patients. Customarily, dyslipidemia is probably the most prevalent underlying cause of untimely demise in people suffering from RA as it hastens the expansion of atherosclerosis. The engagement of inflammatory cytokines like tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), etc., is crucial in the progression and proliferation of both RA and abnormal lipid parameters. Thus, lipid abnormalities should be monitored frequently in patients with both primary and advanced RA stages. An advanced lipid profile examination, i.e., direct role of apolipoproteins associated with various lipid molecules is a more dependable approach for better understanding of the disease and selecting suitable therapeutic targets. Therefore, studying their apolipoproteins is more relevant than assessing RA patients' altered lipid profile levels. Among the various apolipoprotein classes, Apo A1 and Apo B are primarily being focused. In addition, it also addresses how calculating Apo B:Apo A1 ratio can aid in analyzing the disease's risk. The marketed therapies available to control lipid abnormalities are associated with many other risk factors. Hence, directly targeting Apo A1 and Apo B would provide a better and safer option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a apolipoproteins | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a dyslipidemia | |
| 650 | 4 | |a rheumatoid arthritis | |
| 700 | 1 | |a Sharma, Chakshu |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Lalit |e verfasserin |4 aut | |
| 700 | 1 | |a Wal, Pranay |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Preeti |e verfasserin |4 aut | |
| 700 | 1 | |a Sachdeva, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Shivam |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas De-La Cruz, Celia |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniyan, Vetriselvan |e verfasserin |4 aut | |
| 700 | 1 | |a Rawat, Ravi |e verfasserin |4 aut | |
| 700 | 1 | |a Behl, Tapan |e verfasserin |4 aut | |
| 700 | 1 | |a Nandave, Mukesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of physiology and pharmacology |d 1964 |g (2024) vom: 09. Feb. |w (DE-627)NLM000001635 |x 1205-7541 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1139/cjpp-2023-0259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 02 | ||